Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author)
|
|
- Dennis Moore
- 6 years ago
- Views:
Transcription
1 Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact ame and Job Title (author) Directorate & Speciality Date of submission December 2015 Date on which guideline must be reviewed December 2018 Explicit definition of patient group to which it applies Version 3 Changes from previous guideline If this version supersedes another clinical guideline please be explicit about which guideline it replaces including version number Statement of the evidence base of the guideline has the guideline been peer reviewed by colleagues? Evidence base: (1-5) 1 ICE Guidance, Royal College Guideline, SIG (please state which source) 2a Meta analysis of randomised control trials 2b At least one randomised controlled trial 3a at least one well-designed controlled study without 2b randomisation at least one other type of well-designed quasiexperimental study 4 well designed non-experimental descriptive studies (ie comparative / correlation and case studies) 5 expert committee reports or opinions and / or clinical experiences of respected authorities 6 recommended best practise based on the clinical experience of the guideline developer Consultation Process Ratified by: Date Target audience Guideline for the management of Clostridium difficile infection and antibiotic-associated diarrhoea in adults. Dr Vivienne Weston - Consultant Microbiologist Tim Hills - Lead Pharmacist Antimicrobials and Infection Control Heather Abdic - Gastroenterology urse Specialist Dr Kathy Teahon and Prof ash Mahida - Consultant Gastroenterologists Microbiology Diagnostics and Clinical Support For adults with suspected / proven C.difficile infection or antibiotic-associated diarrhoea. Fidaxomicin highlighted, administration of vancomycin using injection orally added to flow chart. HPA / DH ational Guidelines (2009) C. difficile How to Deal With the Problem. Available from: (accessed ). PHE ational Guidelines (2013) Updated guidance on the management and treatment of Clostridium difficile infection. Available from: (accessed ). Summary of product characteristics for Privigen 10%. Available at (accessed ). Personal correspondence with CSL Behring on Miss Walter Consultant Colorectal surgeon Members of ottingham University Hospitals Antibiotic Guidelines Committee. UH antibiotic guidelines committee ovember 2015 Doctors, Registered urses, Pharmacists Review date: December 2018 A review date of 5 years will be applied by the Trust. Directorates can choose to apply a shorter review date, however this must be managed through Directorate Governance processes. This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date. ottingham Antimicrobial Guidelines Committee Page 1 of 10 Written December 2015
2 Figure 1: Antibiotic-associated diarrhoea -Empirical treatment Patient with diarrhoea currently on antibiotic(s) or received antibiotic(s) over preceding 4 weeks Send stool specimen to microbiology for Clostridium difficile toxin (CDT) and check computer for previous microbiology results, See figure 2 once results are available Stop antibiotics if possible or D/W microbiology if continuation essential for the best regimen, review indication for Proton Pump Inhibitors if prescribed (see PPI guidelines) and investigate other causes for diarrhoea e.g. tube feeds, antacids, laxatives Take a FBC, U&E and, if any abdominal pain AXR. Refer to Gastro urse Specialist cdiffgastronurses@nuh.nhs.uk or OTIS- DIARCS for assessment and clinical support Inform Infection Prevention and Control Team (City Ext or QMC Ext 63866) Isolate patient, start enteric precautions and stool chart. Mild disease Mild diarrhoea alone i.e. <4 stools in 24 hours, no features of severe disease Supportive therapy only- these cases are often self-limiting if causative antibiotics are stopped. Moderate disease > 4 stools in 24 hours, no features of severe disease Start PO Metronidazole 400mg tds for 10 days, refer to gastroenterology (nurse specialists OTIS referral Diarrhoea services / out of hours acute gastro team via switch) Severe disease Any of the following regardless of stool frequency :- WBC > 15x 10 9 /L Temp > 38.5 C Acute inc. serum creatinine (>50% baseline) Evidence of severe colitis (hypotension, ileus, pseudomembranous colitis abdominal signs, radiology-ct or Abdo. X-Ray) Start PO/G (not IV) Vancomycin (use injection orally- see page 5) 125mg-250mg qds + refer to acute gastro on-call registrar ASAP (if BM + G route /A IV Metronidazole 500mg tds). Ensure first doses are given immediately. Complicated disease Signs of severe disease complicated by hypotension or partial ileus or CT evidence of severe disease Life threatening disease Complete ileus or Toxic megacolon Start PO/G (not IV) Vancomycin (use injection orally- see page 5) 250mg (if complicated) -500mg (if life threatening) qds plus IV metronidazole 500mg tds refer to acute gastro on-call registrar ASAP plus, if fulminant disease, gastrosurgery Ensure first doses are given immediately. Recurrence of symptoms, Patients should be investigated and treated according to the protocol above with repeat samples but with a second course of whichever antibiotic regimen the original infection responded to (PO Metronidazole/PO Vancomycin or combinations). If the patient is confirmed positive for C.difficile infection and not received fidaxomicin before then start PO fidaxomicin 200mg bd for 10 days (plus stop any vancomycin/metronidazole started) after discussion with microbiology. Pharmacy must be contacted following microbiology approval for urgent supply. Further recurrences should be discussed in hours with Gastroenterology urse (Specialist in C difficile disease)- OTIS DIARCS or cdiffgastronurses@nuh.nhs.uk for both City and QMC or if acutely unwell/severe disease Acute Gastro Registrar (QMC) (City). ottingham Antimicrobial Guidelines Committee Page 2 of 10 Written December 2015
3 Figure 2: Interpretation of Stool Sample Results Stool Sample Result Toxin +ve Toxin ve PCR +ve Toxin -ve Start Treatment See Figure 3 Repeat sample Toxin +ve Review other causes for diarrhoea including medication. If diarrhoea ongoing : Repeat sample. Isolate with enteric precautions. Consider referral to gastro Review other causes of diarrhoea including medication (e.g. laxatives/ PPIs). If diarrhoea ongoing : Repeat sample. If Toxin ve on repeat, unlikely C.diff infection. Consider referral to gastro PCR +ve and Toxin ve on repeat, C.diff colonisation present, infection unlikely. Continue to isolate. Review other causes of diarrhoea. Patient does not require treatment unless severe disease. Repeat sample Toxin +ve ottingham Antimicrobial Guidelines Committee Page 3 of 10 Written December 2015
4 Figure 3: Treatment of Confirmed C.difficile Toxin +ve Cases es to either question, Discuss with microbiology for most appropriate regimen Confirmed Toxin +ve cases Does the patient require concomitant systemic antimicrobials for another infection? Or is this a recurrence of C.diff infection? o to both questions Start PO Fidaxomicin 200mg bd for 10 days following approval from microbiology. All confirmed cases should be referred to the Gastroenterology urse Specialist for assessment and clinical management support. Refer via OTIS-DIARCS or cdiffgastronurses@nuh.nhs.uk in working hours Mild or Moderate symptoms o signs of severe disease Treat if ongoing diarrhoeamay have resolved spontaneously. Start PO metronidazole 400mg tds for 10 days o improvement within 5 days or any clinical deterioration, change to PO (not IV) Vancomycin (use injection orally- see page 5) 125 mg qds for 10/7 if not already started Plus seek gastroenterology / microbiology advice regarding need for further escalation of treatment Severe disease Any of the following regardless of stool frequency:- WBC > 15x 10 9 /L Temp > 38.5 C Acute increase in serum creatinine (>50% baseline) Evidence of severe colitis (hypotension, ileus, pseudomembranous colitis abdominal signs, radiology (CT or Abdo. X-Ray)) Start PO/G (not IV) Vancomycin (use injection orally- see page 5) 125mg-250mg qds + refer to acute gastro on-call registrar ASAP (if BM + G route /A IV Metronidazole 500mg tds) Ensure first doses are given immediately. Complicated disease Signs of severe disease complicated by hypotension or partial ileus or CT evidence of severe disease Life threatening disease Complete ileus or Toxic megacolon Start PO/G (not IV) Vancomycin 250mg (use injection orally- see page 5) (if complicated) -500mg (if life threatening) qds plus IV Metronidazole 500mg tds Refer to acute gastro on-call registrar ASAP plus, if fulminant disease, gastrosurgery Ensure first doses are given immediately. Complete 10 day course, this can be increased to 14 days if on-going diarrhoea or prescribed concurrent antibiotics Once patient stabilises and has a dependable oral/g route, consider stopping IV metronidazole and weaning down vancomycin to 125mg -250mg PO/G qds. Complete a 10 day course, this can be increased to 14 days if on-going diarrhoea or concurrent antibiotics or complicated/life threatening infection. ottingham Antimicrobial Guidelines Committee Page 4 of 10 Written December 2015
5 Remember: 1 Use antibiotics and proton pump inhibitors only when indicated follow trust guidelines. 2 Follow the hospital formulary and prescribing guidelines available at 3 Use narrow spectrum antibiotics whenever possible 4 Review all antibiotics daily, intravenous antibiotics at 48 hours and oral antibiotics at 5 days. Add durations and indications to antibiotic prescriptions. 5 Review empiric treatment with microbiology results. Convert to a narrower spectrum agent if possible. 6 Consider the diagnosis of C. difficile diarrhoea in patients who develop diarrhoea having had antibiotics in the preceding 4 weeks 7 Clearance stools samples are not required. Preparation and Administration of Oral/G Vancomycin for C. difficile Treatment Vancomycin injection is licensed for oral use and is used as a treatment for Clostridium difficile associated diarrhoea at UH. It is keep as stock on the majority of adult wards. Please contact pharmacy ASAP if unavailable. Directions for preparation 1. Reconstitute vancomycin 1g vial with 20ml of Water for Injection to give a concentration of vancomycin 125mg in 2.5ml. 2. Withdraw the required volume (e.g. for 125mg withdraw 2.5ml) and place into a medicine galipot. 3. This may be further diluted with water or squash to approximately 20-30ml before administering. 4. Write the patient s name, date and time of reconstitution and date and time of expiry onto an oral vancomycin sticker (Kept on the ward, flag the vial with the sticker). 5. The solution should be stored in the fridge and is suitable for oral use for up to 24 hours. 6. Vials are for single-patient-use only and should not be shared. Stickers can be ordered from pharmacy stores using an emergency stock requisition. ottingham Antimicrobial Guidelines Committee Page 5 of 10 Written December 2015
6 ADDITIOAL IFORMATIO FOR USE O THE ADVICE OF GASTROETEROLOGISTS/ MICROBIOLOGISTS/ IFECTIOUS DISEASE PHSICIAS Initial Treatment and Assessment of Severity Assess severity of disease each day defining: (i) Mild Disease as three or fewer type 5-7 stools on Bristol Stool Chart per day and no features of severe disease. (ii) Moderate Disease > 4 stools per day and no features of severe disease. (iii) Severe Disease as a WCC >15x 10 9 /L or a temperature of > 38.5 C or acute rising serum creatinine (e.g. >50% increase above baseline) or evidence of severe colitis (abdominal or radiological signs). The number of stools may be a less reliable indicator of severity. (iv) Complicated Disease as hypotension or partial ileus or CT evidence of severe disease. (v) Life threatening Disease as complete ileus or toxic megacolon. Treat according to severity : (i) Mild and Moderate Disease - oral metronidazole 400 mg 8-hourly for 10 days. (ii) Severe Disease - oral vancomycin mg 6-hourly for days. (iii) Complicated Disease - oral vancomycin up to 500mg 6-hourly for days (check random serum vancomycin level at least once, which should be <15mg/L) plus IV metronidazole 500 mg 8-hourly. (iv) Life Threatening - oral vancomycin up to 500mg 6-hourly via naso-gastric tube (check serum vancomycin levels which should be <15mg/L) plus iv metronidazole 500 mg 8-hourly. Such patients should be monitored with serum lactate and colectomy considered especially if caecal dilatation is >10 cm (see below). Once patient stabilises and has a dependable oral/g route, consider stopping IV metronidazole and weaning down vancomycin to mg PO/G qds (usually every 3-7 days according to response). Complete at least a 14 day total course. Refractory Disease As other pathologies can be responsible for ongoing diarrhoea the diagnosis should be reviewed. A flexible sigmoidoscopy, if not contraindicated, to confirm the diagnosis should be considered particularly where the C. difficile toxin is negative or a weak positive. Oral vancomycin dosing should be increased to 250mg qds once the patient has not responded or is deteriorating despite at least a 7-day course of 125mg qds dosing or sooner if the patient is deteriorating. Sigmoidoscopy (excludes haematology and neutropaenic patients) Please contact the Acute Gastro Registrar bleep via switchboard Post-infectious diarrhoea If diarrhoea persists despite 20 days treatment but the patient is stable, the daily number of type 5-7 motions has decreased, the WCC is normal, and there is no abdominal pain or distension, the persistent diarrhoea may be due to post-infectious non-specific causes. If the sigmoidoscopy and biopsy confirms absence of inflammation, the patient may be given a trial of an anti-motility agent such as loperamide 2mg prn (instead of metronidazole or vancomycin) on the advice of gastroenterology, the patient should be reviewed if diarrhoea still persists The patient should be closely observed for evidence of a therapeutic response and to ensure there is no evidence of colonic dilatation. Severe Refractory Disease As other pathologies can be responsible for ongoing diarrhoea the diagnosis should be reviewed. A flexible sigmoidoscopy, if not contraindicated, to confirm the diagnosis should be considered particularly where the C. difficile toxin is negative or a weak positive. ottingham Antimicrobial Guidelines Committee Page 6 of 10 Written December 2015
7 1. Increase oral vancomycin up to 500mg 6-hourly for days (check random serum vancomycin level at least once, which should be <15mg/L) plus IV metronidazole 500 mg 8-hourly. IV metronidazole should be reviewed once disease is under control. Local installation of vancomycin to be considered and maybe advised by a consultant gastroenterologist especially when ileus is evident. 2. Monitor serum lactate 3. Consider referral to Gastro-surgery especially if caecal dilatation is >10 cm Consider IV immunoglobulins (IVIG) Local installation of vancomycin may be advised in severe refractory cases on the advice of a consultant gastroenterologist or colorectal surgeon. Given as a retention enema via rectal Foley catheter as 500mg in ml normal saline maximum qds instilled and clamped for 60 minutes, deflate and remove (monitor serum vancomycin levels should be <15mg/L) or 1g Vancomycin in 100mls saline as a single dose down the colonoscope at the time of colonoscopy. Surgery Best practice is that patients with severe disease should have an initial assessment by the medical and surgical GI registrars. Initial assessment of co-morbidities will identify those for whom aggressive surgical care is contra-indicated. All other patients with severe disease should be reviewed at least twice a day until there is clear evidence of improvement (Temperature, Heart rate, BP and improving WCC). In patients within the severe colitis sub group, criteria for considering surgery should include: WCC > 30x 10 9 /L or < 4x 10 9 /L (a rising WCC despite full dose oral / enteral vancomycin is a good indicator of failing medical therapy) Rising lactate (before the level rises to 5 mmol/l) Hypotension not responding to appropriate fluid resuscitation (but in this context early surgery before the need for vasopressors or intubation is essential) Toxic mega-colon Junior medical and surgical teams should be reminded that: C. diff colitis should be considered when patients present, in the right setting, with acute abdomen, fever and leucocytosis. This can occur without diarrhoea or a (+) C.difficile toxin result The colon can look normal at laparotomy in patients with severe C. difficile colitis Subtotal colectomy and ileostomy is the standard surgery. Those having a left hemicolectomy or defunctioning ileostomy for C. difficile do not usually survive. Post-operative mortality is associated with patients who have an elevated lactate or are ill enough to need pre-operative vasopressors or intubation or in whom there is a delay to surgery Use of Intravenous Immunoglobulins (IVIG) in Severe or Recurrent C.Difficile infection (B requires immunoglobulin panel approval) IVIG may be useful in the following situations For the treatment of fulminant C. difficile infection where the patient fails to respond to maximal therapy, vancomycin PO 500mg qds + IV metronidazole 500mg tds, especially in patients where surgery and Faecal Microbiota Transplant is not an option. To prevent the recurrence of C.difficile infection in patients where other therapy (e.g. tapering vancomycin and rifaximin- see page 8) has failed or is inappropriate. ationally, supplies of IVIG are limited. All potential cases for IVIG treatment should be discussed with Prof Mahida or Dr Weston in hours (or consultant colleagues if out of hours) and require approval from the Trust s immunoglobulin panel, complete the request form on the Immunoglobulin website or choose immunoglobulins on the A-Z list of the Trust intranet). Once the form is submitted supply should be sought from pharmacy (i.e. contact ward pharmacist as appropriate). Prescribing Dose Initially, 0.4 grams/kg as a one-off dose by IV infusion rounding down to the nearest 5 gram vial to conserve supplies. Repeat dose may be given on the following days if clinically required. Consider reducing the ottingham Antimicrobial Guidelines Committee Page 7 of 10 Written December 2015
8 maximum rate of infusion in patients with a history of cardiovascular/ vascular disease and/or thrombotic risk factors. Ensure all patients receive enoxaparin thromboprophylaxis as appropriate. Dosing in Obesity There is no clear guidance regarding dosing in obesity. However as immunoglobulin poorly distributes into adipose tissue using dose determined weight (DDW) to calculate immunoglobulin dosage in obese patients (>20% above their ideal body weight (IBW)) appears most appropriate: IBW for males = 50 + (2.3 x (height in inches- 60)) IBW for females (2.3 x (height in inches- 60)) DDW = IBW (actual body weight (kg) IBW) Administration CAUTIO: Different brands exist with different administration details- Discuss with Pharmacy. PRIVIGE 10% BRAD (1 st Line) Start at 0.3ml per kg /hour for the first 30 minutes, if well tolerated then the rate of administration can be doubled every 30 minutes to a maximum rate of 4.8ml / per kg /hr. Refer to table below. Privigen Infusion Table for Selected Patients Weights Weight (kg) 1 st 30 minutes 2 nd 30 minutes 3 rd 30 minutes 4 th 30 minutes Maximum rate Initial rate 0.3ml / kg /hour 0.6ml / kg /hour 1.2ml / kg /hour 2.4ml / kg /hour 4.8ml / kg /hour 40Kg 12ml/hour 24ml/hour 48ml/hour 96ml/hour 192ml/hour 50Kg 15ml/hour 30ml/hour 60ml/hour 120ml/hour 240ml/hour 60Kg 18ml/hour 36ml/hour 72ml/hour 144ml/hour 288ml/hour 70Kg 21ml/hour 42ml/hour 84ml/hour 168ml/hour 336ml/hour 80Kg 24ml/hour 48ml/hour 96ml/hour 192ml/hour 384ml/hour 90Kg 27ml/hour 54ml/hour 108ml/hour 216ml/hour 432ml/hour 100Kg 30ml/hour 60ml/hour 120ml/hour 240ml/hour 480ml/hour Side effects Allergic reactions, chills / fever, headache, nausea, vomiting, joint pains, low blood pressure and moderate low back pain - consider rate reduction of infusion. Anaphylactic / shock reactions are rare but can occur even in patients who have tolerated previous treatment with normal intravenous immunoglobulin. Rare reports of acute renal failure, aseptic meningitis, transient cutaneous reactions, haemolytic anaemia, associated with thrombotic events- MI, PE, DVT, stroke reassess VTE prophylaxis. Monitoring Monitor the patient (temperature, blood pressure, pulse, respiratory rate) before starting the infusion, throughout the infusion and for 1 hour after the first infusion or 20 minutes after subsequent infusions. Monitor urine output and serum creatinine levels. Storage CAUTIO: Different brands exist with different storage details- Discuss with Pharmacy. Privigen should be stored at room temperature (not above 25 C). General otes: There are several brands of Immunoglobulin routinely stocked at UH. Use Privigen first line. Use the same brand of Immunoglobulin per treatment course. Switching between the brands increases the risk of side effects. ottingham Antimicrobial Guidelines Committee Page 8 of 10 Written December 2015
9 Recurrent Disease Recurrences occur in 20-30% of patients, and are more common in elderly patients, the risk of a further recurrence increases to 40-60%. Patients should be investigated according to the protocol on page two above with repeat samples but should receive treatment with a second empirical course of whichever antibiotic regimen the original infection responded to (PO metronidazole/po vancomycin or combinations). If the patient is confirmed positive for C.difficile infection and has not received fidaxomicin before then start PO fidaxomicin 200mg BD for 10 days (stop any vancomycin/metronidazole started) after discussion with Microbiology. Audit data from 2014/15 confirmed a C.difficile infection recurrence rate of 14.9% when fidaxomicin was used; comparable with results from published trials. More than one recurrence or non-responsive disease If more than 1 recurrence or non-responding disease, advise referral to a gastroenterologist with a specialist interest in C.difficile disease (see below) or the infectious disease team, for confirmation of diagnosis and exclusion of other causes and consideration for the use of tapering therapy +/- Rifaximin if confirmed recurrent disease. Recurrence vancomycin tapering course over 6 weeks Week 1 vancomycin 125mg QDS for 7 days Week 2 vancomycin 125mg TDS for 7 days Week 3 vancomycin 125 mg BD for 7 days Week 4 vancomcyin 125mg OD for 7 days Week 5 vancomcyin 125 mg on alternate days for 7 days Week 6 vancomycin 125mg every third day for 1 week ote on the prescription/ drug chart that this is a tapering course. If further diarrhoea, follow with a full dose course of PO vancomycin 125 mg QDS for days. Rifaximin Rifaximin is on the formulary for the management of recurrent C.difficile on a named patient basis on the advice of Drs Teahon or Prof Mahida, after discussion at the weekly clinical C. difficile multidisciplinary meeting. It is active against C.difficile whilst causing limited disruption of GI flora and poor systemic absorption. It is administered orally, as a follow-up therapy, after a course of oral vancomycin at a dose of rifaximin 400mg BD for 14 days. It may not be held as stock at UH so contact with pharmacy should be made a few days prior to prescribing. IVIG see above Gastroenterology Opinion Consultants - Dr Kathy Teahon (city) / Prof ash Mahida (QMC) Lorraine Clark (Gastroenterology and Endoscopy urse Lead) Gastroenterology urses specialist (in c diff diarrhoea) - Heather Abdic/ Angela Copeland Microbiology Contact Dr Vivienne Weston / QMC or City Duty Medical Microbiologist ottingham Antimicrobial Guidelines Committee Page 9 of 10 Written December 2015
10 Appendix 1 Audit Tool for C.diff infection (Toxin +ve) Personal information Risks for C.diff Hosp. o. K Abx in last 4/52 Date of Audit PPIs Date of Birth Enteral Feeding Previous C.diff Toxin Previous C.diff PCR C.diff Management for each episode Date of diarrhoea onset Date of Toxin result Referral to Gastro C.diff nurse - If es, date of referral Severity according to guideline Mild Moderate Severe Complicated Life (circle) - If Severe/Complicated/Life Threatening was a referral made to the Acute Gastro Team Initial C.diff treatment: Date of referral: Time of referral: threatening - Increased to: - Changed to: Did the patient have colitis (either radiologically or via flexible sigmoidoscopy (PMC) o Evidence If on PPI was it stopped? - If no was the rationale reviewed? Antibiotics preceding C.diff result: Were they in line with guidance? - If not was clinical justification given? Did the patient receive at least 10 days C.diff treatment If first reoccurrence was Fidaxomicin naïve was it prescribed? - If not, why not? If second reoccurrence and already received Fidaxomicin, was tapering Vancomycin prescribed? If the patient died whilst receiving C.diff treatment did C.diff feature on the death certificate - If yes what part of the death certificate ottingham Antimicrobial Guidelines Committee Page 10 of 10 Written December 2015
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationLifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2)
Lifting the lid on a difficile problem part (Clinical) Dr Philip T Mannion Consultant Microbiologist, Rhyl Evidence Based Practice Antibiotic prescribing guidance Isolation policy Hand hygiene (soap and
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationClostridium difficile Infection Antibiotics Guidelines. Contents
Clostridium difficile Infection Antibiotics Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationClinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents
Clinical Clostridium Difficile: Standard Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationAntimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections
Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Version 7.2 PAGL Inclusion Approved at January 2017 PGC APPROVED BY: TRUST REFERENCE: B3/2017 AWP REF: UHL Policies and
More informationAmy-Jo Hooley Specialist Clinical Pharmacist
Gut Decontamination Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the Safe Administration
More informationIntravenous Immunoglobulin (IVIg) prescribing guidance
Intravenous Immunoglobulin (IVIg) prescribing guidance Kejal Mehta (Specialist Pharmacist) [December 2016] Review Date: December 2017 Contents Introduction:... 2 Prior to Intravenous immunoglobulin (IVIg)
More informationClostridium difficile
Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationChapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given
Chapter 5 Gastroenterology Georgia Woodfield TERLIPRESSIN CIPROFLOXACIN 2 initial dose 500 Every 4 hours until bleeding controlled can be reduced to 1 after initial dose if side effects develop or if patient
More informationJoint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics
A clinical guideline recommended For use in: All clinical areas where vancomycin is prescribed for Children aged 1 month to 16 years By: All medical, nursing, pharmacy, microbiology and phlebotomy paediatric
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationFIS 2013, Birmingham
Fidaxomicin: CDDFT Case Studies Dr Deepa Nayar County Durham and Darlington Foundation Trust FIS 2013, Birmingham This meeting has been initiated and funded by Astellas Pharma Ltd. County Durham and Darlington
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationGuideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use
Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationManagement of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
More informationReducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationCARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS This Care Pathway has been developed by a multidisciplinary team. It
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More informationNHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
NHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
More informationHigh Intensity Chemotherapy Guidelines for Haematology Patients at ASPH
High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH Contents: Page No. 1. Overview 2 2. Admission 3 3. Admission Checklist 5 4. Inpatient management during chemotherapy 6 5. Inpatient
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationTrust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)
A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:
More informationGASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT Name & Title Of Author: Dr Linda Jewes, Consultant Microbiologist Date Amended: December 2016 Approved by Committee/Group: Drugs & Therapeutics
More informationDay care adenotonsillectomy in sleep apnoea
Day care adenotonsillectomy in sleep apnoea Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Day care adenotonsillectomy in presence of sleep apnoea 1a 2a 2b Contact
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationNHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion
Acute Sector NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Co-ordinators: Gillian Macartney Fiona McDonald Specialist Antibiotic
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationThis guideline describes the care required for a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guidelines for care of a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS
ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence
More informationDR J HARTY / DR CM RITCHIE / DR M GIBBONS
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Paracetamol Poisoning DR J HARTY / DR CM RITCHIE / DR M GIBBONS Medicine Acute Date Uploaded: 16 th September 2014 Review Date
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationNorth Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance)
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance) Introduction OPAT services provide intravenous (IV) antibiotics to patients
More informationCAUTION: You must refer to the intranet for the most recent version of this procedural document.
Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationProtocol for the Management of Neutropenic Sepsis in Adult Patients P
Protocol for the Management of Neutropenic Sepsis in Adult Patients P Version 2 Date April 2015 Review Date April 2016 Author Rachel Onions Change Approver Acute Oncology Team UHMBT. Version 2. CHANGE
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationGood Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes
Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes This good practice guidance is intended to be used as a framework for care home managers to adapt when writing their
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationTitle Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines. Author s job title
Document Control Title Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines Author Consultant Microbiologist Consultant Paediatrician Consultant
More informationADULT (>16) ACUTE SICKLE PAIN GUIDELINE
ADULT (>16) ACUTE SICKLE PAIN GUIDELINE ID 2013 065 Author s Name Dr Anna Wood Author s Job Title Consultant Haematologist Division Consultant Haematologist Department Haematology Version number 3 Ratifying
More informationPlease inform the Diabetes Nurse Specialist that this patient has been admitted within 24hrs of admission.
Adult Diabetic Ketoacidosis Care Bundle (V1. Issued October 2014 Review October 2015) Improving patient care This pack includes: DKA Management Guideline Name: (Patient Addressograph) DOB: Hospital No:
More informationTitle of Guideline (must include the word Guideline Guideline for the Treatment of Hypokalaemia in Adults
Title of Guideline (must include the word Guideline Guideline for the Treatment of (not protocol, policy, procedure etc) Hypokalaemia in Adults Contact Name and Job Title (author) Emily Snow, Pharmacist
More informationTrust Guideline for the Management of: Condition or Procedure in Adults and / or Children
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children A clinical guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document
More informationNCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease
NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease Hospital Number Admission to hospital 5. Trusts should ensure that medical patients are reviewed by a consultant
More informationAcute Gastroenteritis, Adult Emergency Orders
Form Title Form Number 21003 2018, Alberta Health Services, CKCM This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationHaemophilia Suspected Bleed
Haemophilia Suspected Bleed Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the management
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationDiarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
More informationPaediatric Prescribing Pocket Guide September 2014 (Version 1)
PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors
More informationA Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.
Subject: Neutropenic Fever Guideline for Junior Doctors Date of Implementation: January 2010 Date of Review: January 2012 Director Responsible for Implementation and Review: Policy location: Consultant
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationGuidelines on the Prevention, Detection, And Management of Clostridium difficile Infection
Guidelines on the Prevention, Detection, And Management of Clostridium difficile Infection 1 CLINICAL GUIDELINES CHECKLIST Name of guidelines Guidelines on the Prevention, Detection, and Management of
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationGUIDELINES FOR PERFORMING AN INTRAPERITONEAL UROKINASE LOCK
GUIDELINES FOR PERFORMING AN INTRAPERITONEAL UROKINASE LOCK Contact Name and Job Title (author) Directorate & Speciality Jr Sr Vanessa Keill Diabetes, Infection, Renal and Cardiovascular Directorate (Renal
More informationCare homes - Homely remedies
Bulletin 72 August 2014 Care homes - Homely remedies Care home staff have a recognised duty of care to be able to respond to minor symptoms experienced by residents. A homely remedy is a medicinal product
More informationTrust Guideline for the Management and Administration of Intravenous Iron in Adults under the Gastroenterology Directorate
A clinical guideline recommended for use For Use in: The Gastroenterology Directorate By: Registered nurses competent in the administration of intravenous therapy and medical staff For: Adult patients
More informationGlucocorticoid replacement, Steroids, Acute Illness Dr Rupa Ahluwalia, Consultant Physician (NNUH)
For Use in: By: For: Division responsible for document: Key words: Name and job title of document author s: Name and job tile of document author s Line Manager: Supported by: Assessed and approved by the:
More informationInfection Prevention & Control Core Skills Level 2
Infection Prevention & Control Core Skills Level 2 Learning outcomes Risk assessment of patients Critical examination of the situation MRSA, CDT & CPE Ongoing challenges future-proofing infection control
More informationChapter 14: Training in Radiology. DDSEP Chapter 1: Question 12
DDSEP Chapter 1: Question 12 A 52-year-old white male presents for evaluation of sudden onset of abdominal pain and shoulder pain. His past medical history is notable for a history of coronary artery disease,
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationGastrointestinal Involvement in Adult Mitochondrial Disease
Newcastle Mitochondrial Disease Guidelines At a glance guidelines: Gastrointestinal Involvement in Adult Mitochondrial Disease For full guideline visit: http://www.newcastle-mitochondria.com/service/patient-care-guidelines/
More informationSuboptimal hydration harms patients.
Suboptimal hydration harms patients. NHS Fife is committed to improving hydration management. To achieve this we need your help! In 2014 new fluid balance charts were implemented in the Victoria Hospital,
More informationA Clinical Guideline for the use of Intravenous Aminophylline in Acute Severe Asthma in Children
For Use in: By: For: Division responsible for document: Key words: Name and job titles of document author: Name and job title of document author s Line Manager: Supported by: Assessed and approved by the:
More informationIndex No: MMG11/1. Version: 1. Date ratified: 12 th November 2013
Index No: Intravenous fluid prescription in children For previously well children aged one month to 16 years (excluding renal, cardiac, diabetic ketoacidosis and acute burns patients) Version: 1 Date ratified:
More information